Inaugural
Genomics in Medicine
Individualized Care for Improved Outcomes
February 11-12
Moscone North Convention Center • San Francisco, CA

Symposium Register by January 18, 2013 Save up to $200!

Reasons to Attend
• HEAR keynote presentations from Dr. Hakon Hakonarson of CHOP and Dr. John Iafrate of MGH
• FIND out how to transition genomic screening to the clinic
• DISCOVER evolving approaches to mutation detection
• EXPLORE data management and analysis solutions
• LEARN the role of pharmacogenomics in patient care
• NETWORK with genomic thought leaders
• PARTICIPATE in interactive, problem-solving breakout discussions

Featured Presentations
Genomically-Supported Diagnostic and Drug Reposition Strategies out of Academia
Hakon Hakonarson, M.D., Ph.D., Director, Center for Applied Genomics, Children’s Hospital of Philadelphia

Clinical Cancer Genotyping – Snapshot
John Iafrate, M.D., Ph.D., Assistant Professor, Pathology, Harvard Medical School; Assistant Pathologist, Massachusetts General Hospital

Moving Genomic Screening to the Clinic: Next Steps
Bruce R. Korf, M.D., Ph.D., Wayne H. and Sara Crews Finley Chair in Medical Genetics; Professor and Chair, Department of Genetics; Director, Heflin Center for Genomic Sciences, University of Alabama at Birmingham

Premier Sponsors:

Luminex
ELSEVIER
REMEDY INFORMATICS
Singulex®

Organized by Cambridge Healthtech Institute

TriConference.com
Plenary Keynotes

**Wednesday, February 13 8:00 – 9:40 am**

**Personalized Oncology – Fulfilling the Promise for Today’s Patients**

In honor of the 20th anniversary of the Molecular Medicine Tri-conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs. Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future.

- **Moderator:** Marty Tenenbaum, Ph.D., Founder and Chairman, Cancer Commons; Prominent AI Researcher; Cancer Survivor
- **Tony Blau, M.D.,** Professor, Department of Medicine/Hematology and Adjunct Professor, Department of Genome Sciences, University of Washington; Attending Physician, Seattle Cancer Care Alliance; Co-Director, Institute for Stem Cell and Regenerative Medicine, University of Washington and the Program for Stem and Progenitor Cell Biology at the UW/FHCRC Cancer Consortium; Founder and Scientific Officer, Partners in Personal Oncology
- **Sarah Greene,** Executive Director, Cancer Commons
- **Jane Reese-Coulbourne, MS, ChE,** Executive Director, Reagan-Udall Foundation for the FDA; former Board Chair, Lung Cancer Alliance; Cancer Survivor
- **Anil Sethi,** CEO, Pinch Bio; HL7 Pioneer and Health Informatics Entrepreneur
- **Joshua Stuart, Ph.D.,** Associate Professor, Department of Biomolecular Engineering, University of California Santa Cruz

**Thursday, February 14 8:00 – 9:40 am**

**Plenary Keynote Panel: Emerging Technologies & Industry Perspectives**

This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included.

- **Moderator:** To be Announced
- **Gregory Parekh, Ph.D.,** CEO, Biocartis
- **Kevin Bobofchak, Ph.D.,** Pathway Studio Product Manager, Elsevier
- **Jeremy Bridge-Cook, Ph.D.,** Senior Vice President, Research & Development, Luminex Corporation
- **Panelist to be Announced, Remedy Informatics
- **Harry Glorikian,** Managing Partner, Scientia Advisors, LLC
- **Lynn R. Zieske, Ph.D.,** Vice President, Commercial Solutions, Singulex, Inc.

2013 Sponsors

**Premier Sponsors:**

- Luminex
- REMEDY INFORMATICS
- Singulex

**Corporate Sponsors:**

- BioMerieux
- Agencourt
- Agilent Technologies
- Almac
- ALIMAK
- AMGEN
- ANNEXIN/AMARANTHUS INC
- ATCC
- BioFortis
- BIORAD
- CAMBRIDGE GENETICS
- Chem.Optics
- CDD
- CYCLIC COMPUTING
- DOTPEOPLE
- DRACSTAR
- DNA Software
- Exemplar Solutions
- Fidelta
- GeneXo
- Genomatrix
- GTG
- IDBS
- IGEM
- INGENIETY
- International Genomics
- JPL
- Life Sciences
- Life Technologies
- LifeMatrix
- Luminex
- METADON
- MRI
- MYRIAD RBM
- NanoString
- OMEGA
- ORIGENE
- Pacific Biosciences
- Pathway Studio
- Predictive Bioinformatics
- PrimeraDx
- QUINTILES
- Randox
- RareCells
- ResearchDx
- Rheonix
- Schrödinger
- ScrenCell
- Seegene
- ScienTifica
- ScienTifica Advisors
- SeqIn
- SimulConsult
- SOLIA
- Sony DADC
- Somalogic
- SonoSite
- Sunquesthealth
- TESSELLA
- TESSA
- TESSA Health
- VIVO

Sponsored by

- AMERICAN GENOMICS
- BIOTEAM
- BIOTEAM BioScience
- CYNVENIO
- CYTOSYSTEMS
- ProMab Biotechnologics, Inc.
Conference Programs:
Feb 13-15

**Diagnostics Channel**
- Molecular Diagnostics
- Personalized Diagnostics
- Cancer Molecular Markers
- Circulating Tumor Cells
- Digital Pathology – NEW
- Companion Diagnostics – NEW

**Therapeutics Channel**
- Mastering Medicinal Chemistry
- Cancer Biologics
- Clinical and Translational Science

**Clinical Channel**
- Oncology Clinical Trials
- Clinical and Translational Science
- Clinical Sequencing – NEW

**Informatics Channel**
- Bioinformatics in the Genome Era
- Integrated R&D Informatics and Knowledge Management

**Cancer Channel**
- Cancer Molecular Markers
- Circulating Tumor Cells
- Predictive Pre-Clinical Models in Oncology – NEW
- Oncology Clinical Trials
- Cancer Biologics

Symposia*:
Feb 11-12
- Targeting Cancer Stem Cells
- Genomics in Medicine – NEW
- Point-of-Care Diagnostics
- Quantitative Real-Time PCR – NEW
- Next Generation Pathology

Partnering Forum*:
Feb 11-12
- Emerging Molecular Diagnostics

Short Courses*:
Feb 12
1:30-4:30pm
- SC1 Identification & Characterization of Cancer Stem Cells
- SC2 Commercialization Boot Camp: Manual for Success in the Molecular Diagnostics Marketplace
- SC3 NGS Data and the Cloud
- SC4 Best Practices in Personalized and Translational Medicine
- SC5 Latest Advances in Molecular Pathology
- SC6 Regulatory Approval of a Therapeutic & Companion Diagnostic: Nuts & Bolts
- SC7 PCR Part I: qPCR in Molecular Diagnostics
- SC8 Data Visualization
- SC9 Methods for Synthesis & Screening of Macroyclic Compound Libraries

5:00-8:00pm (Dinner)
- SC10 PCR Part II: Digital PCR Applications and Advances
- SC11 Sample Prep and Biorepositories for Cancer Research
- SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications
- SC13 Strategies for Companion Diagnostics Development
- SC14 Patient-Derived Cancer Tissue Xenograph Models
- SC16 Microfluidics Technology and Market Trends
- SC17 Open Cloud & Data Science

Co-located Event

**BayBio Entrepreneur & Investor Roundtables**
February 14, 2013, 4:00-7:00 pm
Connect with corporate venture, angel investors and VCs
www.baybioroundtables.com

*Separate reg required with a la carte pricing

---

TRI-CON All Access Package

Get the best 5-day value! Our All Access Packages is a convenient, cost-effective way to attend each aspect of Molecular Med TRI-CON 2013. Package includes access to 1 Symposium or Partnering Forum, 2 Short Courses and 1 Conference Program.
MONDAY, FEBRUARY 11

7:30 am Registration and Morning Coffee

8:25 Chairperson’s Opening Remarks

Screening for Rare and Difficult to Diagnose Diseases

8:30 KEYNOTE PRESENTATION: Genomically-Supported Diagnostic and Drug Reposition Strategies out of Academia

Hakon Hakonarson, M.D., Ph.D., Director, Center for Applied Genomics, Children’s Hospital of Philadelphia

This talk will discuss genomic strategies applied in academia to identify subsets of patients who, based on their genetic make-up, are predicted to have a favorable response profile to drugs that come from reposition opportunities.

9:00 Evolving Approaches to Mutation Detection in Rare Diseases

Tom Scholl, Vice President, Research & Development, Integrated Genetics, LabCorp

Emerging trends in this field that include the expansion of content in clinical tests to include many loci and increased clinical sensitivity by expanding numbers of mutations detected or whole gene sequencing will be presented.

9:30 From Raw Sequencing Data to Functional Interpretation

Daniel MacArthur, Ph.D., Group Leader, Analytic and Translational Genetics Unit, Massachusetts General Hospital

This presentation will discuss the key lessons learned from large-scale sequencing studies in both common and rare diseases with a particular focus on finding mutations underlying severe muscle diseases.

10:00 Coffee Break with Exhibit and Poster Viewing

10:30 Providing Whole Genome Sequencing in the Clinic

David Dimmock, M.D., Assistant Professor, Pediatrics, Medical College of Wisconsin

This presentation will focus on advances in the implementation of genome wide sequencing in clinical practice. It will address counseling and consent issues specific to testing children. Specifically, it will highlight the challenges of execution in the acute care setting.

11:00 Clinical Utility of Whole Exome Sequencing

Christine M. Eng, M.D., Professor, Department of Molecular and Human Genetics, Baylor College of Medicine

This presentation will discuss the role of whole exome sequencing in the diagnostic evaluation of patients with challenging phenotypes of genetic etiology. Examples of clinical utility, directed medical care, and cost-effectiveness of the whole exome approach to clinical diagnostics will be presented.

11:30 A Neuronal Carnitine Deficiency Hypothesis for Autism

Arthur L. Beaudet, M.D., Henry and Emma Meyer Professor and Chair, Department of Molecular and Human Genetics, Baylor College of Medicine

We have published a paper entitled “A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism” (PMID: 22566635). We propose a neuronal carnitine deficiency hypothesis as one risk factor or cause for autism whereby 10-20% of autism might be preventable.

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

Predictive Tests for Improved Patient Outcomes

1:25 Chairperson’s Remarks

1:30 Implementation of Personalized Healthcare into Clinical Practice: Lessons Learned

Kathryn Teng, M.D., FACP, Director, Center for Personalized Healthcare, Cleveland Clinic

Integrating a pharmacogenetics program into clinical practice requires a vision for the future of healthcare and a roadmap to reach that vision. Pioneering the road to achieving this vision has brought challenges and has allowed for the creation of solutions that might be applied universally.

2:00 Molecular Profiling of Tumors to Select Therapy in Patients with Advanced Refractory Tumors

Ramesh Ramanathan, M.D., Medical Director, The Virginia G. Piper Cancer Center Clinical Trials

This presentation will discuss molecular profiling of tumors using IHC, CGH and whole genome/exome sequencing of tumors to find actionable targets for therapy. Clinical trials and case reports of patients treated by this approach will be presented.

2:30 Sponsored Presentations (Opportunities Available)

3:00 Refreshment Break with Exhibit and Poster Viewing

3:30 Gene Panels vs. Whole Exome Sequencing in Cancer Molecular Testing

Madhuri Hegde, Ph.D., FACMG, Associate Professor, Senior Director, Emory Genetics Laboratory, Department of Human Genetics, Emory University School of Medicine
4:00 Next Generation Sequencing and Cancer Diagnostics
Phil Stephens, Ph.D., Vice President, Cancer Genomics, Foundation Medicine
Foundation Medicine has developed FoundationOne™, a CLIA-certified, comprehensive cancer genomic test that analyzes routine clinical specimens for somatic alterations in 189 relevant cancer genes. Experience with the initial 1,000 consecutive patients will be presented.

4:30 KEYNOTE PRESENTATION: Clinical Cancer Genotyping – Snapshot
John Iafrate, M.D., Ph.D., Assistant Professor, Pathology, Harvard Medical School; Assistant Pathologist, Massachusetts General Hospital
The challenges and opportunities of implementing a broad genotyping assay in routine clinical management of cancer patients will be discussed. Snapshot was launched over 3 years ago at the Massachusetts General Hospital, with the goal of providing all cancer patients with a genetic fingerprint to guide therapeutic decisions. Lessons learned will be outlined, and a roadmap to effectively move testing forward into the Next Gen sequencing era.

5:00 Breakout Discussions (See Web for Details)

6:00 Close of Day

TUESDAY, FEBRUARY 12

8:00 am Morning Coffee

Data Management and Analysis

8:10 Chairperson’s Remarks

8:15 Under the Hood of the 1000 Genomes Project
Mark A. DePristo, Ph.D., Associate Director, Medical and Population Genetics Analysis, Broad Institute of MIT and Harvard (on behalf of The 1000 Genomes Project Consortium)
This presentation discusses the evolution of the next-generation sequencing (NGS) data underlying the public 1000 Genomes Project resource, from some of the earliest technologies of 2009 to today’s state-of-the-art data. It will also highlight key NGS analytic advances originating from the Project.

8:45 Delivering Genomic Medicine: Challenges and Opportunities
Heidi L. Rehm, Ph.D., FACMG, Assistant Professor, Pathology, BWH and Harvard Medical School; Director, Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine
This talk will cover the speaker’s experience in offering clinical sequencing to patients, from disease-targeted panels to whole genome analyses as well as supporting the interpretation and delivery of those results to physicians. It will also cover approaches to data sharing within the community.

9:15 From Sequence Files to Physicians Report and the Tools Needed to Get There
Martin Seifert, Ph.D., CEO, Genomatix Software
Providing actionable biology from NGS data in a report useful to the practicing clinician is difficult. Ensuring the report is accurate, reproducible, and reflects the biology of the patient is an even larger task. We will show examples of Genomatix’ approach to these issues and how we successfully ensure a secure, accurate, and reproducible report, bridging the gap from sequencer to clinician.

9:30 Rapid Identification of Disease Causative Mutations
Ali Torkamani, Ph.D., Co-Founder & CSO, Cypher Genomics
Recent successes in clinical genome sequencing have highlighted the potential for sequencing to greatly improve molecular diagnosis and clinical decision-making. However, these successes have relied upon large bioinformatics teams and in-depth literature surveys. We will demonstrate how the Cypher Genomics software service can quickly return a small set of well-annotated genetic variants most likely to contribute to a patient’s disease.

10:00 Coffee Break with Exhibit and Poster Viewing

Getting Genomic Testing to Clinic

10:30 Sequence Data on Demand: Access, Visualization and Communication of Genome Sequence Data between Physicians, Researchers, and Patients
Sitharthan Kamalakaran, Ph.D., Senior Member, Research Staff, Philips Research North America
Patients’ genome sequences are informative for clinical care over the patient’s lifetime and not just for the diagnosis at hand. We present a web-accessible interface for clinicians to integrate relevant patient genome data in their routine practice through clinically-framed queries.

11:00 Targeted Next Generation Sequencing in FFPE Tumor Samples: Distilling High Quality Information from Low Quality Samples
Diane Ilsley, Ph.D., Marketing Manager, Asuragen, Inc.
SuraSeq™ PCR-based enrichment procedures enable accurate and sensitive mutation detection from nanogram inputs of challenging FFPE tumor DNA. Case studies will be presented that highlight the use of complementary NGS platforms and novel bioinformatics for discovery and confirmation studies.
11:30 Transitioning New Technologies from the Bench to the Bedside: Direct Fetal Testing Using Circulating Cell-Free DNA
Allan T. Bombard, M.D., CMO, Sequenom
This presentation will address clinical test implementation of new tests in the US, using circulating cell-free DNA for noninvasive prenatal testing (NIPT) of fetal aneuploidy from maternal plasma as an example.

12:00 Moving Genomic Screening to the Clinic: Next Steps
Bruce R. Korf, M.D., Ph.D., Wayne H. and Sara Crews Finley Chair in Medical Genetics; Professor and Chair, Department of Genetics; Director, Heflin Center for Genomic Sciences, University of Alabama at Birmingham
Since the sequencing of the human genome there has been an expectation that a flood of advances would find their way to the clinic, and, indeed, the pace of translation of genomics to clinical application is accelerating. It is likely that the future of medical care will evolve by the convergence of two disruptive technologies — that of information science and genomics, which, in a sense can be viewed as one and the same.

12:30 pm Close of Symposium

Recommended Programs:
Main Conference
- Personalized Diagnostics

Short Courses
- NGS Data and the Cloud
- PCR Part I: qPCR in Molecular Diagnostics
- NGS in Molecular Pathology
- PCR Part II: Digital PCR Applications and Advances
Hotel Information

Reserve your hotel and save $100 off your conference registration*

*You must book your reservation under the Tri-Conference room block for a minimum of 4 nights at the Marriott or the Intercontinental Hotel. One discount per hotel room.

Conference Venue:
The Moscone North Convention Center
747 Howard Street
San Francisco, CA 94103
www.moscone.com

Host Hotel:
San Francisco Marriott Marquis
55 Fourth Street
San Francisco, CA 94103
(T) 415-896-1600
Reservations: 888-575-8934
Discounted Group Rate: $229 s/d
Cutoff Date: January 14, 2013
* Room Rate includes complimentary internet access in your guestroom

Additional Recommended Hotel:
InterContinental San Francisco Hotel
888 Howard Street
San Francisco, CA 94103
(T) 415-616-6500
Discounted Group Rate: $235 s/d
Cut Off Date: January 14, 2013

Sponsorship & Exhibit Opportunities

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space and branding, as well as the use of the pre and post-show delegate lists. Signing on early will allow you to maximize exposure to hard-to-reach decision makers.

Breakfast & Luncheon Presentations
Opportunities may include a 15 or 30-minute podium presentation during the main agenda. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. Packages include: exhibit space, on-site branding, and more.

Invitation-Only VIP Dinner/Private Receptions
Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor’s objectives.

Exhibit
Exhibitors will enjoy facilitated networking opportunities with 3,000 highly-targeted delegates at the overall event. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

Inquire about additional branding opportunities, including our Valentine’s Day Soiree Sponsorship!

Looking for additional ways to drive leads to your sales team? CHI can help!

We offer clients numerous options for custom lead generation programs to address their marketing and sales needs, including:

- Live Webinars
- White Papers
- Market Surveys
- Podcasts and More!

For sponsorship & exhibit information, please contact:

Companies A-K
Jon Stroup, Manager, Business Development
781-972-5483 • jstroup@healthtech.com

Companies L-Z
Joseph Vacca, Manager, Business Development
781-972-5431 • jvacca@healthtech.com

Please visit TriConference.com to make your reservations online or call the hotel directly to reserve your sleeping accommodations. You will need to identify yourself as a Molecular Med Tri-Con attendee to receive the discounted room rate with the host hotel. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space- and rate-availability basis. Rooms are limited, so please book early.
## PRICING AND REGISTRATION INFORMATION

### TRI-CON ALL ACCESS PACKAGE - BEST VALUE! (FEB 11-15)

<table>
<thead>
<tr>
<th>Includes 1 Symposium or Partnering Forum, 2 Short Courses, and 1 Conference Program.</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advance Registration until January 18, 2013</td>
<td>$3195</td>
<td>$1845</td>
</tr>
<tr>
<td>Registration after January 18, 2013</td>
<td>$3250</td>
<td>$1930</td>
</tr>
</tbody>
</table>

### Regular Pricing – A La Carte Options

#### PARTNERING FORUM (Monday, Feb 11 – Tuesday, Feb 12)
- **Emerging Molecular Diagnostics** $1450

#### SYMPOSIA (Monday, Feb 11 – Tuesday, Feb 12)
- **S1 Targeting Cancer Stem Cells**
- **S2 Genomics in Medicine**
- **S3 Point-of-Care Diagnostics**
- **S4 Quantitative Real-Time PCR**
- **S5 Next Generation Pathology**

#### SHORT COURSES (Tuesday, Feb 12)

**1 Short Course**

- **Afternoon**
  - SC1 Identification & Characterization of Cancer Stem Cells
  - SC2 Commercialization Boot Camp: Manual for Success in the Molecular Diagnostics Marketplace
  - SC3 NGS Data and the Cloud
  - SC4 Best Practices in Personalized and Translational Medicine
  - SC5 Latest Advances in Molecular Pathology
  - SC6 Regulatory Approval of a Therapeutic & Companion Diagnostic: Nuts & Bolts
  - SC7 PCR Part I: qPCR in Molecular Diagnostics
  - SC8 Data Visualization
  - SC9 Methods for Synthesis & Screening of Macrocyclic Compound Libraries

**2 Short Courses**

- **Dinner**
  - SC10 PCR Part II: Digital PCR Applications and Advances
  - SC11 Sample Prep and Biorepositories for Cancer Research
  - SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications
  - SC13 Strategies for Companion Diagnostics Development
  - SC14 Patient-Derived Cancer Tissue Xenograph Models
  - SC16 Microfluidics Technology and Market Trends
  - SC17 Open Cloud & Data Science

#### CONFERENCE PROGRAMS (Wednesday, Feb 13 - Friday, Feb 15)

**Advance Registration until January 18, 2013**
- $2145
- **Registration after January 18, 2013**
- $2345

### Diagnostics Channel
- **P1 Molecular Diagnostics**
- **P2 Personalized Diagnostics**
- **P3 Cancer Molecular Markers**
- **P4 Circulating Tumor Cells**
- **P5 Digital Pathology – NEW**
- **P6 Companion Diagnostics – NEW**

### Therapeutics Channel
- **P7 Mastering Medicinal Chemistry Summit**
- **P9 Cancer Biologics**
- **P11 Clinical and Translational Science**

### Clinical Channel
- **P10 Oncology Clinical Trials**
- **P11 Clinical and Translational Science**
- **P12 Clinical Sequencing – NEW**

### Informatics Channel
- **P13 Bioinformatics**
- **P14 Integrated R&D Informatics & Knowledge Management**

### Cancer Channel
- **P3 Cancer Molecular Markers**
- **P4 Circulating Tumor Cells**
- **P5 Predictive Pre-Clinical Models in Oncology – NEW**
- **P10 Oncology Clinical Trials**
- **P9 Cancer Genetics**

### CONFERENCE DISCOUNTS
- **Dinner**
- **SC10 PCR Part II: Digital PCR Applications and Advances**
- **SC11 Sample Prep and Biorepositories for Cancer Research**
- **SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications**
- **SC13 Strategies for Companion Diagnostics Development**
- **SC14 Patient-Derived Cancer Tissue Xenograph Models**
- **SC16 Microfluidics Technology and Market Trends**
- **SC17 Open Cloud & Data Science**

### Poster Submission:
- **Poster ($50 Off) – Alumni (20% Off) – BayBio (20% Off)**
- **Alumni Discount SAVE 20%**: We appreciate your past participation at the Molecular Med TRI-CON. Through loyalty like yours, this event has become a must-attend for senior level decision makers. As a result of your great loyalty, we are pleased to extend this exclusive opportunity to save an additional 20% off the registration rate.
- **Hotel Discount ($100 Off)**: Reserve your hotel and save $100 OFF your conference registration *you must book your reservation under the Tri-Conference room block for a minimum of 4 nights.*

**Poster Submission**
- Discount ($50 Off) Dedicated poster sessions for Symposia and Conference Programs. Present your poster at both! **Poster abstracts are due by December 21, 2012.** Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com.
- **One poster discount per registration.**

**REGISTER 3 - 4TH IS FREE**: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply. Additional discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472.

Please use keycode **GDX F** when registering!

How to Register: **TriConference.com**

reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288